Eli Lilly launches $8.5B debt offering across multiple maturities and coupon rates

Eli Lilly and Company filed an underwriting agreement to issue $8.5 billion in aggregate principal amount of notes across eight tranches maturing between 2028 and 2066, with rates ranging from floating to 5.700%. The offering demonstrates strong institutional demand for investment-grade pharmaceutical company debt in the current market environment.